Dr. GPCR and Eurofins DiscoverX Join Forces to Accelerate GPCR Drug Discovery
- Dr. GPCR News
- 18 hours ago
- 2 min read
Boston, MA and San Diego, CA — [February 18, 2026] — Dr. GPCR, the global knowledge hub for G protein-coupled receptor (GPCR) research and education, today announced a strategic partnership with Eurofins DiscoverX, a global leader in GPCR product solutions including cell-based assay product solutions supporting drug discovery, development, and regulatory submission.
This partnership is designed to support the GPCR research community by expanding access to validated, industry-standard GPCR assay platforms that enable rigorous pharmacological characterization and confident decision-making across the discovery and development continuum.
Drawing on more than 25 years of GPCR expertise, Eurofins DiscoverX delivers one of the industry’s most comprehensive GPCR assay portfolios, encompassing over 90% of the human GPCRome with assays for human receptors, species orthologs, and orphan receptors across various cellular backgrounds. Their cell-based assays support a wide range of mechanisms of action, including cAMP accumulation, β-arrestin recruitment, receptor internalization, calcium flux, and ligand binding, generating multidimensional datasets trusted by leading pharmaceutical and biotechnology companies worldwide.
Eurofins DiscoverX assay solutions are used throughout GPCR drug discovery workflows, from target identification and validation to high-throughput screening (HTS), lead optimization, safety assessment, and regulatory-compliant potency testing. These assays are widely accepted by industry and regulators and are supported by thousands of peer-reviewed publications and billions of screened data points.
“Eurofins DiscoverX is distinguished by its deep GPCR expertise and close collaboration with customers,” said Dr. Yamina Berchiche, Founder and CEO of Dr. GPCR. “They offer more than assays—they build true scientific partnerships that help teams get the most from their data and advance GPCR research with confidence.”
“Dr. GPCR plays a critical role in educating and connecting the global GPCR community,” said Geoffrey Donsimoni, GPCR Marketing Director at Eurofins DiscoverX. “Through this collaboration, we look forward to sharing scientific insight, best practices, and real-world applications that help researchers fully leverage GPCR assay technologies across discovery and development.”
Together, Dr. GPCR and Eurofins DiscoverX aim to accelerate GPCR-targeted drug discovery by connecting scientists with proven assay platforms, deep pharmacological expertise, and expert-driven context that supports better experimental design and data interpretation.
To explore Eurofins DiscoverX GPCR assay solutions and curated resources, visit:
To learn more about Dr. GPCR’s educational programs and global GPCR community, visit
About Dr. GPCR
Dr. GPCR is a nonprofit organization connecting the global GPCR community through training, curated news, expert-led courses, and networking. With over 180 podcast episodes, live and on-demand educational programs, and a growing partner ecosystem, Dr. GPCR empowers scientists and organizations advancing GPCR biology and GPCR-targeted drug discovery.
About Eurofins DiscoverX
Eurofins DiscoverX is a global leader in GPCR cell-based assay technologies, providing industry-standard, regulatory-accepted platforms spanning basic research, drug discovery, and development. With more than 25 years of expertise and coverage of over 90% of the human GPCRome, Eurofins DiscoverX assays are trusted by leading pharmaceutical companies worldwide to generate high-quality, decision-enabling pharmacological data.
Comments